The Specialty Drug Problem: Why One Prescription Can Break a Small Group Plan Year

A member starts a biologic for rheumatoid arthritis in month three of the plan year. The drug costs $6,500 per month. By month six, the pharmacy claims for that single member exceed what the plan spent on routine medical care for the other fourteen employees combined. The claims fund, set at $240,000 for the year based on actuarial expectation, is 42 percent consumed by one prescription before anyone else’s medical costs are counted.

This is the specialty drug problem in small group level funded plans. It is not a gradual trend. It is a structural exposure that arrives as a recurring monthly claim, with annual costs ranging from $50,000 for common biologics to $500,000 or more for rare disease therapies. The exposure is growing. The FDA approved 50 novel drugs in 2024, continuing an average of 46.5 novel approvals per year over the past decade. Oncology led the pipeline with 16 approvals. Twenty-six of the 50 received orphan drug designation for rare diseases, a category that reliably produces high-cost therapies with small patient populations and premium pricing. The specialty drug problem is not episodic. It is structural, and the pipeline is accelerating it.

The Scale of Exposure

#

Specialty drugs account for approximately 2 to 3 percent of prescription volume in commercially insured populations but represent more than half of total drug spending. IQVIA’s Michael Kleinrock, executive director of the IQVIA Institute, has described the concentration precisely: specialty drugs consume a small fraction of prescriptions but dominate spend, and for smaller self-insured employers, a single member on a $300,000 annual therapy can change the economics of the plan overnight. In 2024, specialty medications accounted for $262 billion in net branded sales in the United States, representing 53 percent of branded net revenue, up from 49 percent in 2018.

The cost range spans two orders of magnitude. Adalimumab biosimilars now run $40,000 to $55,000 per year, down from the Humira reference product’s peak pricing above $80,000. But newer autoimmune agents and oncology therapies launch at higher price points. The IQVIA Institute reported that the median annual treatment cost for new drugs launched in 2023 exceeded $150,000, with oncology and orphan therapies driving the upper range. Rare disease therapies routinely exceed $300,000 per year. Enzyme replacement therapies for lysosomal storage disorders such as Fabry disease or Gaucher disease can reach $400,000 to $500,000 annually.

For a 15-person employer with $240,000 in expected annual claims, the arithmetic does not leave room for interpretation. One member on a $100,000 specialty drug consumes 42 percent of the claims fund. One member on a $200,000 drug consumes 83 percent. Two members on $75,000 biologics consume 63 percent. The remaining claims budget covers medical costs, traditional pharmacy, and all other utilization for the entire group.

Total U.S. net spending on medicines reached $487 billion in 2024, an 11.4 percent increase over 2023, the largest growth rate since the COVID-19 vaccine launches of 2021. Overall pharmaceutical expenditures hit $805.9 billion across all channels. IQVIA projects that total net spending will reach $600 billion by 2029, with growth of 3 to 6 percent per year after discounts and rebates. The specialty categories, particularly oncology and obesity, are expected to drive the majority of that increase.

Stop Loss Interaction

#

The stop loss architecture exists to protect small groups from catastrophic individual claims. The interaction between specialty drug costs and stop loss is mechanically sound but creates renewal consequences that compound across plan years.

When a member begins a recurring specialty drug, the claims typically breach the specific stop loss attachment point within the first plan year. A 15-person group with a $75,000 specific attachment point, standard for groups of that size, will see the attachment point exceeded by month two for a member on a drug costing $6,250 per month. From that point, the stop loss carrier absorbs the cost above the deductible. The catastrophic exposure is capped. The mechanism works.

The underwriting consequences arrive at renewal. If the stop loss carrier anticipated the drug during underwriting, the attachment point and premium already reflect the expected cost. The renewal may be stable. If the drug was new, undisclosed, or began mid-year, the carrier faces claims it did not price for. The carrier’s response at renewal is predictable: a laser. The laser raises the specific attachment point for that individual member above their expected claims, effectively excluding the known drug cost from stop loss protection. A member on a $100,000 annual drug may face a specific attachment point of $150,000 or $175,000 at renewal, pushing the entire predictable cost back to the employer’s claims fund.

For small groups, lasering at renewal following a year with specialty drug claims is standard practice across stop loss carriers including Sun Life, Voya, Symetra, and Tokio Marine HCC. The employer faces three choices at renewal: accept the laser and absorb the known drug cost directly; pay a substantially higher premium for no-laser coverage, which may price the stop loss above the employer’s budget; or shop the group to another carrier, who will likely laser the known risk themselves after reviewing the group’s claims history.

The aggregate stop loss corridor adds pressure from a different angle. Aggregate coverage activates when total plan claims exceed a threshold, typically 120 to 125 percent of expected claims. A $100,000 specialty drug in a $240,000 expected claims pool pushes the aggregate corridor thin. If that drug coincides with even moderate utilization from the rest of the group, total claims can breach the aggregate attachment point. The aggregate payout provides relief in the current year, but the aggregate premium at renewal will reflect the experience.

The Pipeline

#

The specialty drug problem is accelerating. The FDA approved 50 novel drugs in 2024, 55 in 2023. The ten-year rolling average now stands at 46.5 per year, a record. Of the 2024 approvals, 66 percent used at least one expedited pathway: fast track, breakthrough therapy, priority review, or accelerated approval. The 21st Century Cures Act of 2016 created additional expedited pathways for regenerative medicine therapies. The Orphan Drug Act continues to incentivize development of drugs for rare diseases with populations under 200,000, a framework that reliably produces therapies priced above $100,000 per year.

IQVIA projects an average of 50 to 55 new drug launches per year through 2029, with oncology, specialty, and orphan drug designations accounting for the majority. The late-stage pipeline visible in ClinicalTrials.gov contains hundreds of biologics, antibody-drug conjugates, and targeted therapies in Phase 2 and Phase 3 development. Oncology leads. Autoimmune disease follows. Neurology, including the anti-amyloid Alzheimer’s therapies addressed in LFP-09.04, represents a growing category of chronic high-cost therapy for aging workforces.

Biosimilar competition provides partial relief for older reference biologics. The adalimumab biosimilar market has produced measurable savings since launch in 2023. Evernorth reported that Humira biosimilars generated over $200 million in savings from January 2024 through March 2025, averaging $4,505 per patient per year. As of June 2025, the FDA had approved 71 biosimilars across 19 reference products, with 53 launched across 14 categories. But the net effect across the full specialty drug category remains inflationary. New launches outpace biosimilar erosion. IQVIA projects specialty drug spending to grow 5 to 8 percent per year at list prices through 2029. For every dollar biosimilars save on adalimumab or infliximab, new launches in oncology, rare disease, and neurology add multiple dollars in new spending.

For small group level funded plans, the pipeline means the probability that any given member will be prescribed a high-cost specialty drug increases each year. Conditions that were untreatable a decade ago now have $100,000 therapies. Conditions managed with $5,000 annual regimens now have $50,000 alternatives with superior efficacy. The problem is not static. It compounds across plan years.

Plan Design Responses

#

Plan design offers tools for managing specialty drug exposure. None addresses the underlying pricing. All shift cost, restrict access, or both.

Specialty tiers place high-cost drugs in a separate cost-sharing category with coinsurance of 20 to 50 percent rather than flat copays. For a $75,000 drug, 30 percent coinsurance produces $22,500 in annual member cost-sharing before the out-of-pocket maximum applies. Once the member reaches the out-of-pocket maximum, typically $9,200 for individual coverage and $18,400 for family coverage under 2025 ACA limits, the plan absorbs the remainder. Specialty tiers shift a portion of the first-year cost to the member but do not eliminate the plan’s exposure.

Prior authorization adds clinical gatekeeping before the plan covers a specialty drug. The prescribing physician must document diagnosis, treatment history, and clinical appropriateness. Prior authorization ensures the drug is clinically indicated. It does not reduce the cost for members who meet the criteria. Ten states have enacted gold card laws exempting providers with consistently high approval rates from routine prior authorization requirements, which may increase access and reduce administrative friction but does not affect the underlying drug cost.

Step therapy protocols require members to try lower-cost alternatives before the plan covers a high-cost therapy. A member prescribed a newer biologic may need to try a biosimilar or conventional disease-modifying agent first. Step therapy reduces costs when members respond to lower-cost alternatives. It adds administrative burden and delays access for members who will ultimately require the high-cost drug after failing first-line options.

Copay accumulator and copay maximizer programs address manufacturer copay assistance cards. Under traditional plan designs, manufacturer assistance counts toward the member’s deductible and out-of-pocket maximum, allowing the plan to begin paying sooner. Accumulator programs exclude manufacturer assistance from the out-of-pocket calculation, requiring the member to satisfy cost-sharing with their own money. Maximizer programs extend manufacturer assistance across the full plan year by adjusting cost-sharing monthly. Both programs shift cost back to manufacturers and members. They are subject to state regulation, with multiple states restricting or banning accumulator programs. The programs are controversial because they can affect medication adherence, particularly for members who cannot afford the out-of-pocket burden once manufacturer assistance is exhausted. IQVIA reported that payer accumulator and maximizer programs accounted for $4.8 billion in copay assistance in 2024, more than double the 2019 level.

These plan design mechanisms are necessary. A level funded plan without prior authorization, specialty tiers, or utilization management faces uncontrolled exposure. But the mechanisms are insufficient. They manage the employer’s share of a cost set by manufacturers. A $100,000 drug remains a $100,000 drug after prior authorization confirms the member qualifies. The specialty drug problem in small group level funded plans reflects the collision between the pharmaceutical industry’s pricing trajectory and the small risk pool’s structural inability to absorb high-cost variance. Plan design mitigates the exposure. Stop loss caps the catastrophe while creating renewal risk. The problem does not have a solution available to the individual employer or TPA. It is a feature of the market structure that level funded plans operate within.